Ivermectin Formulation

1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Ivermectin Formulation

Manufacturer or supplier’s details
Company: MSD
Address: No. 485 Jing Tai Road
Pu Tuo District - Shanghai - China 200331
Telephone: +1-908-740-4000
Emergency telephone number: 86-571-87268110
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product

2. HAZARDS IDENTIFICATION

Emergency Overview
Appearance: oily
Colour: light yellow
Odour: characteristic

May be harmful if swallowed. May cause damage to organs. May cause damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects.

GHS Classification
Acute toxicity (Oral): Category 5
Specific target organ toxicity - single exposure: Category 2
Specific target organ toxicity - repeated exposure: Category 2
Short-term (acute) aquatic hazard: Category 1
Long-term (chronic) aquatic hazard: Category 1

GHS label elements
Hazard pictograms:

Signal word: Warning
Hazard statements : H303 May be harmful if swallowed.
                  H371 May cause damage to organs.
                  H373 May cause damage to organs through prolonged or re-
                  peated exposure.
                  H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:
                           P260 Do not breathe mist or vapours.
                           P264 Wash skin thoroughly after handling.
                           P270 Do not eat, drink or smoke when using this product.
                           P273 Avoid release to the environment.
                           Response:
                           P308 + P311 IF exposed or concerned: Call a POISON
                           CENTER/ doctor.
                           P391 Collect spillage.
                           Storage:
                           P405 Store locked up.
                           Disposal:
                           P501 Dispose of contents/ container to an approved waste
                           disposal plant.

Physical and chemical hazards
Not classified based on available information.

Health hazards
May be harmful if swallowed. May cause damage to organs. May cause damage to organs
through prolonged or repeated exposure.

Environmental hazards
Very toxic to aquatic life. Very toxic to aquatic life with long lasting effects.

Other hazards which do not result in classification
None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components
<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivermectin</td>
<td>70288-86-7</td>
<td>&gt;= 1 -&lt; 2.5</td>
</tr>
<tr>
<td>2,6-Di-tert-butyl-p-cresol</td>
<td>128-37-0</td>
<td>&gt;= 0.25 -&lt; 1</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-
               vice immediately. When symptoms persist or in all cases of doubt seek medical
               advice.
**SAFETY DATA SHEET**

according to GB/T 16483 and GB/T 17519

**Ivermectin Formulation**

---

**Version** 2.1  | **Revision Date:** 2021/08/27  | **SDS Number:** 6097530-00003  | **Date of last issue:** 2020/11/04  | **Date of first issue:** 2020/06/30

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.
Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed : May be harmful if swallowed.
May cause damage to organs.
May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

---

**5. FIREFIGHTING MEASURES**

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during firefighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

---

**6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
- Soak up with inert absorbent material.
- For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
- Clean up remaining materials from spill with suitable absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 7. HANDLING AND STORAGE

**Handling**
- **Technical measures**: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- **Local/Total ventilation**: Use only with adequate ventilation.
- **Advice on safe handling**: Do not breathe mist or vapours.
  - Do not swallow.
  - Avoid contact with eyes.
  - Avoid prolonged or repeated contact with skin.
  - Wash skin thoroughly after handling.
  - Handle in accordance with good industrial hygiene and safe practice, based on the results of the workplace exposure assessment.
  - Do not eat, drink or smoke when using this product.
  - Take care to prevent spills, waste and minimize release to the environment.
- **Avoidance of contact**: Oxidizing agents

**Storage**
- **Conditions for safe storage**: Keep in properly labelled containers.
  - Store locked up.
  - Store in accordance with the particular national regulations.
- **Materials to avoid**: Do not store with the following product types:
  - Strong oxidizing agents
- **Packaging material**: Unsuitable material: None known.

### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

**Components with workplace control parameters**

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivermectin</td>
<td>70288-86-7</td>
<td>TWA</td>
<td>0.05 mg/m3 (OEB 3)</td>
<td>Internal</td>
</tr>
</tbody>
</table>
Further information: Skin

<table>
<thead>
<tr>
<th></th>
<th>Wipe limit</th>
<th>0.5 mg/100 cm²</th>
<th>Internal</th>
</tr>
</thead>
<tbody>
<tr>
<td>2,6-Di-tert-butyl-p-cresol</td>
<td>128-37-0</td>
<td>TWA (Inhalable fraction and vapor)</td>
<td>2 mg/m³</td>
</tr>
</tbody>
</table>

**Engineering measures**: Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

**Personal protective equipment**

**Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

- **Filter type**: Particulates type
- **Eye/face protection**: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection**: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**Hand protection**

- **Material**: Chemical-resistant gloves
- **Remarks**: Consider double gloving.

**Hygiene measures**: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. **PHYSICAL AND CHEMICAL PROPERTIES**

- **Appearance**: oily
## Ivermectin Formulation

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colour</td>
<td>light yellow</td>
</tr>
<tr>
<td>Odour</td>
<td>characteristic</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>167.5 °C</td>
</tr>
<tr>
<td>Flash point</td>
<td>219.2 °C</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapour density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>0.88 - 0.92</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td>Water solubility: practically insoluble</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>Viscosity, kinematic: No data available</td>
</tr>
<tr>
<td>Explosive properties</td>
<td>Not explosive</td>
</tr>
<tr>
<td>Oxidizing properties</td>
<td>The substance or mixture is not classified as oxidizing.</td>
</tr>
</tbody>
</table>
Molecular weight: No data available
Particle size: Not applicable

10. STABILITY AND REACTIVITY
Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: Can react with strong oxidizing agents.
Conditions to avoid: None known.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION
Exposure routes:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
May be harmful if swallowed.

Product:
Acute oral toxicity: Acute toxicity estimate: 5,000 mg/kg
Method: Calculation method

Acute dermal toxicity: Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:
Ivermectin:
Acute oral toxicity: LD50 (Rat): 50 mg/kg
LD50 (Mouse): 25 mg/kg
LD50 (Monkey): > 24 mg/kg
Target Organs: Central nervous system
Symptoms: Vomiting, Dilatation of the pupil
Remarks: No mortality observed at this dose.

Acute inhalation toxicity: LC50 (Rat): 5.11 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rabbit): 406 mg/kg
LD50 (Rat): > 660 mg/kg

2,6-Di-tert-butyl-p-cresol:
Acute oral toxicity: LD50 (Rat): > 6,000 mg/kg
Method: OECD Test Guideline 401

Acute dermal toxicity: LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation
Not classified based on available information.

Components:

Ivermectin:
Species: Rabbit
Result: No skin irritation

2,6-Di-tert-butyl-p-cresol:
Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation
Remarks: Based on data from similar materials

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Ivermectin:
Species: Rabbit
Result: Mild eye irritation

2,6-Di-tert-butyl-p-cresol:
Species: Rabbit
Method: OECD Test Guideline 405
Result: No eye irritation
Remarks: Based on data from similar materials

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Ivermectin:
Exposure routes: Dermal
Species: Humans
Result: Does not cause skin sensitisation.
**SAFETY DATA SHEET**
according to GB/T 16483 and GB/T 17519

**Ivermectin Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>2021/08/27</td>
<td>6097530-00003</td>
<td>2020/11/04</td>
<td>2020/06/30</td>
</tr>
</tbody>
</table>

**2,6-Di-tert-butyl-p-cresol:**

- **Test Type**: Human repeat insult patch test (HRIPT)
- **Exposure routes**: Skin contact
- **Species**: Humans
- **Result**: negative

**Germ cell mutagenicity**
Not classified based on available information.

**Components:**

**Ivermectin:**

- **Genotoxicity in vitro**
  - Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
- **Genotoxicity in vitro**
  - Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
  - Test system: human diploid fibroblasts
  - Result: negative
- **Genotoxicity in vitro**
  - Test Type: Mouse Lymphoma
  - Result: negative

**2,6-Di-tert-butyl-p-cresol:**

- **Genotoxicity in vitro**
  - Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
  - Test Type: In vitro mammalian cell gene mutation test
  - Result: negative
  - Test Type: Chromosome aberration test in vitro
  - Result: negative
- **Genotoxicity in vivo**
  - Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
  - Species: Rat
  - Application Route: Ingestion
  - Result: negative

**Carcinogenicity**
Not classified based on available information.

**Components:**

**Ivermectin:**

- **Species**: Rat
- **Application Route**: Oral
- **NOAEL**: 1.5 mg/kg body weight
- **Result**: negative
- **Remarks**: Based on data from similar materials
Ivermectin Formulation

Species: Mouse
Application Route: Oral
NOAEL: 2.0 mg/kg body weight
Result: negative
Remarks: Based on data from similar materials

2,6-Di-tert-butyl-p-cresol:
Species: Rat
Application Route: Ingestion
Exposure time: 22 Months
Result: negative

Reproductive toxicity
Not classified based on available information.

Components:

Ivermectin:
Effects on fertility: Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 0.6 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on foetal development: Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 0.4 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected.
Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development
Species: Rabbit
Application Route: Oral
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

2,6-Di-tert-butyl-p-cresol:
Effects on fertility: Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development:
- Test Type: Embryo-foetal development
- Species: Rat
- Application Route: Ingestion
- Result: negative

STOT - single exposure
May cause damage to organs.

Components:
Ivermectin:
- Target Organs: Central nervous system
- Assessment: Causes damage to organs.

STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.

Components:
Ivermectin:
- Target Organs: Central nervous system
- Assessment: Causes damage to organs through prolonged or repeated exposure.

2,6-Di-tert-butyl-p-cresol:
- Assessment: No significant health effects observed in animals at concentrations of 100 mg/kg bw or less.

Repeated dose toxicity

Components:
Ivermectin:
- Species: Dog
- NOAEL: 0.5 mg/kg
- LOAEL: 1 mg/kg
- Application Route: Oral
- Exposure time: 14 Weeks
- Target Organs: Central nervous system
- Symptoms: Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species: Monkey
- NOAEL: 1.2 mg/kg
- Application Route: Oral
- Exposure time: 2 Weeks
- Remarks: No significant adverse effects were reported

Species: Rat
- NOAEL: 0.4 mg/kg
- LOAEL: 0.8 mg/kg
Ivermectin Formulation

Application Route: Oral
Exposure time: 3 Months
Target Organs: spleen, Bone marrow, Kidney

2,6-Di-tert-butyl-p-cresol:
Species: Rat
NOAEL: 25 mg/kg
Application Route: Ingestion
Exposure time: 22 Months

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Ivermectin:
Skin contact: Remarks: Can be absorbed through skin.
Eye contact: Remarks: May irritate eyes.
Ingestion: Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Ivermectin:
Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 0.000025 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity): 10,000
M-Factor (Chronic aquatic toxicity): 10,000
## Ivermectin Formulation

<table>
<thead>
<tr>
<th>Component</th>
<th>Toxicity to fish</th>
<th>Toxicity to daphnia and other aquatic invertebrates</th>
<th>Toxicity to algae/aquatic plants</th>
<th>M-Factor (Acute aquatic toxicity)</th>
<th>Toxicity to fish (Chronic toxicity)</th>
<th>Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)</th>
<th>M-Factor (Chronic aquatic toxicity)</th>
<th>Toxicity to microorganisms</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2,6-Di-tert-butyl-p-cresol:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>LC50 (Danio rerio (zebra fish)): &gt; 0.57 mg/l</td>
<td>EC50 (Daphnia magna (Water flea)): 0.48 mg/l</td>
<td>ErC50 (Pseudokirchneriella subcapitata (green algae)): &gt; 0.24 mg/l</td>
<td></td>
<td>NOEC (Oryzias latipes (Japanese medaka)): 0.053 mg/l</td>
<td>NOEC (Daphnia magna (Water flea)): 0.316 mg/l</td>
<td></td>
<td>EC50: &gt; 10,000 mg/l</td>
</tr>
<tr>
<td></td>
<td>Exposure time: 96 h</td>
<td>Exposure time: 48 h</td>
<td>Exposure time: 72 h</td>
<td></td>
<td>Exposure time: 30 d</td>
<td>Exposure time: 21 d</td>
<td></td>
<td>Exposure time: 3 h</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biodegradability</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Result: Not readily biodegradable.</td>
<td>Biodegradation: 4.5 %</td>
<td>Biodegradation: 50 %</td>
<td>Exposure time: 240 d</td>
<td></td>
<td>Exposure time: 28 d</td>
<td>Method: OECD Test Guideline 301C</td>
<td></td>
</tr>
</tbody>
</table>

## Persistence and degradability

### Components:

- **Ivermectin:** Biodegradability: Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 240 d

- **2,6-Di-tert-butyl-p-cresol:** Biodegradability: Result: Not readily biodegradable. Biodegradation: 4.5 % Exposure time: 28 d Method: OECD Test Guideline 301C
Bioaccumulative potential

Components:

Ivermectin:
Bioaccumulation: Bioconcentration factor (BCF): 74
Partition coefficient: n-octanol/water: log Pow: 3.22

2,6-Di-tert-butyl-p-cresol:
Bioaccumulation: Species: Cyprinus carpio (Carp)
Bioconcentration factor (BCF): 330 - 1,800
Partition coefficient: n-octanol/water: log Pow: 5.1

Mobility in soil
No data available

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG
UN number: UN 3082
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Ivermectin, 2,6-Di-tert-butyl-p-cresol)
Class: 9
Packing group: III
Labels: 9

IATA-DGR
UN/ID No.: UN 3082
Proper shipping name: Environmentally hazardous substance, liquid, n.o.s.
(Ivermectin, 2,6-Di-tert-butyl-p-cresol)
Class: 9
Packing group: III
Labels: Miscellaneous
Packing instruction (cargo aircraft): 964
Packing instruction (passenger aircraft): 964
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Ivermectin Formulation

Version 2.1 Revision Date: 2021/08/27 SDS Number: 6097530-00003 Date of last issue: 2020/11/04 Date of first issue: 2020/06/30

Environmentally hazardous: yes

IMDG-Code
UN number: UN 3082
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Ivermectin, 2,6-Di-tert-butyl-p-cresol)
Class: 9
Packing group: III
Labels: 9
EmS Code: F-A, S-F
Marine pollutant: yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations
GB 6944/12268
UN number: UN 3082
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Ivermectin, 2,6-Di-tert-butyl-p-cresol)
Class: 9
Packing group: III
Labels: 9

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

National regulatory information
Law on the Prevention and Control of Occupational Diseases

The components of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
IECSC: not determined

16. OTHER INFORMATION

Further information
Date format: yyyy/mm/dd

15 / 16
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Ivermectin Formulation

Full text of other abbreviations
ACGIH : USA. ACGIH Threshold Limit Values (TLV)
ACGIH / TWA : 8-hour, time-weighted average

 Disclaimer
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN